Recent Quotes (30 days)
You have no recent quotes
| VXX | 12.22 | -0.830-6.36% |  |
| TCP | 51.64 | -1.92-3.58% | |
| MSFT | 52.30 | +0.9201.79% | |
| GOOGL | 717.78 | +10.521.49% | |
| GOOG | 705.63 | +10.271.48% | |
| PTR | 68.15 | +1.982.99% | |
| WFC | 47.79 | +0.9902.12% | |
| BIDU | 159.80 | -3.62-2.22% | |
| BABA | 78.99 | -0.360-0.45% | |
| HUM | 158.15 | -4.59-2.82% | |
| SBUX | 56.51 | -0.400-0.70% | |
| F | 13.09 | +0.3402.67% | |
| GE | 32.20 | +0.3801.19% | |
| FCX | 11.20 | +0.5304.97% | |
| EMC | 27.51 | +0.1800.66% | |
| GM | 29.66 | +0.9203.20% | |
| KGC | 5.53 | +0.1402.60% | |
| CAR | 34.61 | +3.7112.01% | |
| JUNO | 27.81 | -13.01-31.87% | |
| PSMT | 83.39 | -8.16-8.91% | |
48.53
-3.57
(-6.85%)
Jul 8 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 46.80 - 49.99 |
| 52 week | 38.41 - 89.84 |
| Open | 49.32 |
| Vol / Avg. | 0.00/995,473.00 |
| Mkt cap | 2.22B |
| P/E | - |
| Div/yield | - |
| EPS | -2.85 |
| Shares | 49.13M |
| Beta | - |
| Inst. own | 85% |
Events
Aug 8, 2016
Q2 2016 Kite Pharma Inc Earnings Release (Estimated)
- 4:00PM EDT -
Jun 7, 2016
Kite Pharma Inc at Goldman Sachs Global Healthcare Conference
Jun 7, 2016
Kite Pharma Inc at Jefferies Healthcare Conference
Jun 1, 2016
Kite Pharma Inc Annual Shareholders Meeting
May 9, 2016
Q1 2016 Kite Pharma Inc Earnings Call
May 9, 2016
Q1 2016 Kite Pharma Inc Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '16) | 2015 | |
| Net profit margin | -856.56% | -589.02% |
| Operating margin | -892.94% | -598.67% |
| EBITD margin | - | -588.84% |
| Return on average assets | -25.40% | -18.85% |
| Return on average equity | -29.23% | -20.78% |
| Employees | 185 | - |
| CDP Score | - | - |
Address
2225 Colorado Ave
SANTA MONICA, CA 90404-3505
United States - Map
+1-310-8249999 (Phone)
+1-302-6365454 (Fax)
SANTA MONICA, CA 90404-3505
United States - Map
+1-310-8249999 (Phone)
+1-302-6365454 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Prices are not from all markets.
Sources include SIX.
Prices are not from all markets.
Sources include SIX.
Advertisement
Description
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.
Officers and directors
| Arie S. Belldegrun | Executive Chairman of the Board, President, Chief Executive Officer, Founder | |
| Paul L. Jenkinson | Chief Financial Officer | |
| Cynthia M. Butitta | Chief Operating Officer | |
| David D Chang M.D., Ph.D. | Executive Vice President - Research and Development, Chief Medical Officer | |
| Helen S. Kim | Executive Vice President - Business Development | |
| Timothy L. Moore | Executive Vice President - Technical Operations | |
| Margo R. Roberts Ph.D. | Chief Scientific Officer | |
| Marc D. Better Ph.D. | Vice President - Product Sciences | |
| Rizwana F. Sproule | Vice President - Regulatory Affairs | |
| Jeffrey Wiezorek M.D. | Vice President - Clinical Development |